Elevai Labs' Elevai Skincare Inc., Launches Clinical Study Combining Its Flagship Topical Exosome Skincare Products With A Medical Aesthetic Energy Device
Elevai Labs' Elevai Skincare Inc., Launches Clinical Study Combining Its Flagship Topical Exosome Skincare Products With A Medical Aesthetic Energy Device
-
In Collaboration with Renowned Aesthetic Medicine Expert Dr. Jennifer Pearlman, Elevai's Study Will Investigate the Impact of Combining Exosome Skincare with Advanced Energy-Based Treatments for Optimal Skin Rejuvenation
-
As the Global Energy-Based Aesthetic Device Market Is Projected to Reach $5.60 Billion by 2030, Elevai's Study Seeks to Unlock the Full Potential of Combining Exosome Skincare Products with These Technologies for Enhanced Facial Rejuvenation
- Elevai的研究将与著名的美容医学专家詹妮弗·珀尔曼博士合作，研究将外泌体护肤与先进的能量疗法相结合以实现最佳皮肤再生的影响
- 预计到2030年，全球能量型美容设备市场将达到56.0亿美元，Elevai的研究旨在释放将外泌体护肤产品与这些技术相结合以增强面部年轻化的全部潜力
NEWPORT BEACH, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced the initiation of a clinical study to assess the efficacy of a topical exosome product in conjunction with an energy device treatment on facial skin appearance.
加利福尼亚州纽波特海滩，2024年10月2日（GLOBE NEWSWIRE）——医学美容领域的先驱力量Elevai Labs, Inc.（纳斯达克股票代码：ELAB）（“Elevai” 或 “公司”）今天宣布启动一项临床研究，以评估外用外泌体产品联合能量设备治疗对面部皮肤外观的疗效。
The clinical study will assess the efficacy of Elevai's topical exosomes Elevai empower, a topical exosome serum designed specifically for in-office application, and Elevai enfinity, a daily topical exosome product for at home use, as standalone treatments and in conjunction with an energy device treatment on facial skin appearance. The objective of the study is to investigate the efficacy of a topical exosome product on facial appearance after daily use for up to 12 weeks.
该临床研究将评估Elevai的局部外泌体Elevai Empower（一种专为办公室内使用而设计的局部外泌体精华）和Elevai enfinity（一种供家庭使用的日常局部外泌体产品）作为独立治疗的功效，并与能量设备治疗面部皮肤外观结合使用。该研究的目的是研究局部外用外泌体产品在每天使用长达12周后对面部外观的功效。
Elevai is collaborating with Dr. Jennifer Pearlman, an internationally recognized leader in regenerative and aesthetic medicine, and Medical Director of the PearlMD Rejuvenation clinic in Toronto, Canada. She is a board-certified Fellow of Regenerative Medicine (FAARM) by the American Academy of Anti-Aging Medicine (A4M), an expert in Menopause credentialed by NAMS attending physician at Mount Sinai Hospital in Toronto and serves as Faculty teaching at the major international functional medicine meetings. She is faculty and Director of Women's Health at Geneva College of Longevity Science, and a Global Ambassador for the Aesthetic Multispecialty Society, the largest network of cosmetic physicians in the world. Dr. Pearlman is co-founder of Healthspan Digital an AI powered Longevity platform enabling networks to offer leading edge longevity services and practices medicine as a board-certified medical doctor licensed in the Canadian province of Ontario and in the United States in both New York and Florida.
Elevai正在与国际公认的再生和美容医学领袖、加拿大多伦多PearlMD Rejuvenation诊所的医学总监詹妮弗·珀尔曼博士合作。她是美国抗衰老医学学会（A4M）认证的再生医学研究员（FAARM），获得多伦多西奈山医院NAMS主治医生认证的更年期专家，并在主要的国际功能医学会议上任教。她是日内瓦长寿科学学院的教师兼女性健康主任，也是美容多专业协会的全球大使，该协会是世界上最大的美容医生网络。珀尔曼博士是Healthspan Digital的联合创始人，Healthspan Digital是一个由人工智能驱动的长寿平台，使网络能够以董事会认证的医生的身份在加拿大安大略省以及美国纽约和佛罗里达州获得执照，提供前沿的长寿服务和执业医学。
